Clostridium difficile in Immunocompromised Hosts: A Review of Epidemiology, Risk Factors, Treatment, and Prevention
- 7 March 2019
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 68 (12) , 2144-2153
Abstract
Clostridium difficile is a significant pathogen in healthcare today, impacting both hospitalized and community-based patients. Immunocompromised patients experience a high incidence of C. difficile infection, ranging from 6% to 33% in the hematology-oncology population and up to 23% among lung transplant recipients, and have a rate of 7.1-8.3 cases per 1000 patient-years in patients with human immunodeficiency virus (HIV). Recurrence of C. difficile infections among immunocompromised patients is also high, with rates up to 40% in both the hematology-oncology population and solid organ transplant recipients. This higher incidence of C. difficile infection and recurrence is believed to be secondary to frequent antimicrobial use, suppressed immune function, increased exposure to healthcare settings, and higher prevalence of C. difficile colonization. This review summarizes published data describing the epidemiology, risk factors for acquisition and infection, treatment, and prevention of C. difficile in hematology-oncology, solid organ transplant, and HIV-infected patients.Keywords
This publication has 47 references indexed in Scilit:
- Clostridium difficile in a HIV-infected cohortAIDS, 2013
- Clostridium difficile infection increases mortality risk in lung transplant recipientsThe Journal of Heart and Lung Transplantation, 2013
- Clostridium difficile Infection after Adult Autologous Stem Cell Transplantation: A Multicenter Study of Epidemiology and Risk FactorsTransplantation and Cellular Therapy, 2013
- Fidaxomicin versus Conventional Antimicrobial Therapy in 59 Recipients of Solid Organ and Hematopoietic Stem Cell Transplantation with Clostridium difficile-Associated DiarrheaAntimicrobial Agents and Chemotherapy, 2013
- Resolution ofClostridium difficile–Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or VancomycinJournal of Clinical Oncology, 2013
- Epidemiology, risk factors, and outcomes of Clostridium difficile infection in kidney transplant recipientsTransplant Infectious Disease, 2012
- Outcome ofClostridium difficile-associated disease in solid organ transplant recipients: a prospective and multicentre cohort studyTransplant International, 2012
- Clostridium Difficile ColitisTransplantation, 2012
- Epidemiology and Outcomes of Clostridium difficile Infections in Hematopoietic Stem Cell Transplant RecipientsClinical Infectious Diseases, 2012
- Management of diarrhea induced by tumors or cancer therapyCurrent Opinion in Oncology, 1995